
Hematologic Oncology
Latest News

Latest Videos

CME Content
More News

Matthew S. Davids, MD, Associate Director, Dana-Farber Cancer Institute Center for Chronic Lymphocytic Leukemia, discusses a study that explored optimizing checkpoint blockade as a treatment for relapsed hematologic malignancies after allogenic hematopoietic cell transplantation.


















Key opinion leaders share their insight on the pivotal and highly anticipated abstracts across hematologic malignancies, including lymphoma, leukemia, and multiple myeloma, ahead of 2017 ASH Annual Meeting and exactly how these findings could be implemented in and affect clinical practice.

The FDA has lifted partial clinical holds placed on the phase I CheckMate-039 and phase II CA204142 trials exploring nivolumab-based regimens in patients with relapsed/refractory multiple myeloma.

















































